TARDBP and Parkinson disease: Our hypothesis is supported by APOE4 increasing the risk of several age-related disorders, including cardiovascular disease, type 2 diabetes mellitus [64], LBD [20,21,27], TDP-43 pathology severity [25,26], and cognitive decline in late Parkinson’s disease [65,66].